Weiping Zou, M.D., Ph.D.
Tumor immunotherapoloty and immunotherapy, with an emphasis on cross-talk among immune cell subsets, stromal cells, tumor cells and tumor stem cells in the tumor microenvironment, and its impact on tumor immunity, tollerance and therapy.
Kryczek I, Lin Y, Nagarsheth N, Peng D, Zhao L, Zhao E, Vatan L, et al. IL-22(+)CD4(+) T cells promote colorectal cancer stemness via STAT3 transcription factor activation and induction of the methyltransferase DOT1L. Immunity 2014;40:772-784.
Cui TX, Kryczek I, Zhao L, Zhao E, Kuick R, Roh MH, Vatan L, et al. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2. Immunity 2013;39:611-621.
Tanikawa T, Wilke CM, Kryczek I, Chen GY, Kao J, Nunez G, Zou W. Interleukin (IL)-10 ablation promotes tumor development, growth and metastasis. Cancer Res 2011.
Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, Szeliga W, Moyer J, et al. Human TH17 Cells Are Long-Lived Effector Memory Cells. Sci Transl Med 2011;3:104ra100.
Kryczek I, Wu K, Zhao E, Wei S, Vatan L, Szeliga W, Huang E, et al. IL-17(+) regulatory T cells in the microenvironments of chronic inflammation and cancer. J Immunol 2011;186:4388-4395.
Wilke CM, Wang L, Wei S, Kryczek I, Huang E, Kao J, Lin Y, et al. Endogenous interleukin-10 constrains Th17 cells in patients with inflammatory bowel disease. J Transl Med 2011;9:217.
Zou W, Restifo NP. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010;10:248-256.
Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467-477.
Wei S, Kryczek I, Edwards RP, Zou L, Szeliga W, Banerjee M, Cost M, et al. Interleukin-2 Administration Alters the CD4+FOXP3+ T-Cell Pool and Tumor Trafficking in Patients with Ovarian Carcinoma. Cancer Res 2007;67:7487-7494.
Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006;203:871-881.